Simple Summary Over the last decade, immune checkpoint inhibitors (ICIs) targeting
programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T …

Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in
incidence and have a poor prognosis. Most patients present with advanced disease, for …

Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Background The prognosis of patients with advanced biliary tract cancer who have
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …

Introduction: Biliary tract cancer (BTC) is a heterogeneous group of aggressive malignancies
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …

Highlights•Surgical resection remains the mainstay of cure for BTC.•Adjuvant therapy for 6
months with capecitabine is recommended after surgery.•Palliative treatment: CisGem …

Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many
biological processes. Deregulated FGFR signaling plays an important role in tumor …